Non-small cell lung cacner
Conditions
Interventions
None listed
Sponsors
Department of Respiratory Medicine Kumamoto University Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with histologically or cytologically diagnosed non-small cell lung cancer 2. Patients who receive treatment including immune checkpoint inhibitors (monotherapy or combination therapy) as initial therapy (However, patients with driver gene mutations who have previously been treated with molecular targeted drugs are also acceptable) 3. Patients with her PS 0-2 at enrollment 4. Patients with self-determination ability over 20 years old 5. Patients with written consent
Exclusion criteria
Exclusion criteria: 1. Patients under the age of 20 2. Patients who cannot consent to participate in this study 3. Patients who have insufficient decision-making ability and cannot obtain written informed consent from the patient 4. Patients who are judged to be inappropriate as research subjects by the principal investigator or co-investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Objective response rate 2) Overall survival 3) Immune-related adverse events | — |
Countries
Japan
Contacts
Public ContactKoichi Saruwatari
Kumamoto University Medical Sciences Department of Respiratory Medicine
Outcome results
None listed